In this article, we will list the 5 Dirt Cheap Stocks to Buy With $1000 Right Now. Please visit the 8 Dirt Cheap Stocks to Buy With $1000 Right Now if you’d like to see an extended list and the methodology behind it.

5. FactSet Research Systems Inc. (NYSE:FDS)

On March 26, FactSet Research Systems Inc. (NYSE:FDS) announced the expansion of its AI capabilities with the beta rollout of its AI-powered Document Search to more than 85,000 users. The tool helps financial professionals quickly access insights from unstructured data, including filings, earnings calls, and news. The feature improves productivity by offering source-linked results, fast, natural-language search, and company comparison tools, while maintaining auditability and compliance.

The company said the launch builds on its broader AI strategy, including integrations with Claude and ChatGPT, as well as other AI-driven tools.  These efforts support its move toward a unified platform powered by advanced analytics. The beta started in January, with a wider global rollout planned through late spring 2026.

Kate Stepp, Chief AI Officer at FactSet Research Systems Inc. (NYSE:FDS), said:

AI is fundamentally altering the financial landscape, and FactSet is proud to set the standard for trustworthy, impactful adoption. Our achievements highlight not only industry-leading advancements but also our steadfast commitment to providing compliant, auditable intelligence wherever our clients need it most.

Earlier, on March 17, Ashish Sabadra from RBC Capital reduced his price target on FactSet Research Systems Inc. (NYSE:FDS) from $320 to $243 while keeping a Sector Perform rating. The price target adjustment was based on the concerns around potential disruption from GenAI.

FactSet Research Systems Inc. (NYSE:FDS) provides enterprise solutions and operates a financial digital platform for the investment community. The company provides analytics, data, and applications, along with tools such as portfolio analytics, workstations, and enterprise data solutions.

4. Novo Nordisk A/S (NYSE:NVO)

On March 27, Novo Nordisk A/S (NYSE:NVO) said that the U.S. Food and Drug Administration approved Awiqli injection (700 units/mL), a once-weekly long-acting basal insulin for adults with type 2 diabetes. It is used along with exercise and diet to help control blood sugar levels. The company highlighted that this is the first and only basal insulin that needs to be taken once a week, offering patients a more flexible treatment option.

The approval is based on results from the  ONWARDS phase 3a program, which included about 2,680 adults with uncontrolled type 2 diabetes. In these studies, Awiqli was tested in combination with mealtime insulin or other common diabetes treatments such as oral drugs and  GLP-1 receptor agonists. The trials compared once-weekly Awiqli with daily basal insulin and showed that it effectively reduced HbA1c levels.

Earlier, on March 26, Hims & Hers Health announced that it started selling Novo Nordisk A/S (NYSE:NVO)’s GLP-1 drugs Wegovy (semaglutide) and Ozempic (semaglutide) for weight loss and type 2 diabetes. The launch follows a resolved dispute between the two companies, which now limits Hims & Hers Health’s ability to offer most compounded semaglutide versions.

Novo Nordisk A/S (NYSE:NVO) is involved in the manufacture, development, research, and distribution of pharmaceutical products. The company operates in the Rare Disease and Obesity & Diabetes Care segments. It was incorporated in 1923 and is based in Bagsvaerd, Denmark.

3. Baidu Inc (NASDAQ:BIDU)

On March 31, Baidu’s Robotaxi ambitions took a hit when it faced a technical glitch during operations. Several of its Apollo Go Robotaxis stopped abruptly, inconveniencing passengers and disrupting their daily schedules. This has also raised concerns around the viability of its autonomous vehicles among travelers and investors alike.

This also comes as a blow to Baidu’s international ambitions, especially in terms of getting safety and regulatory approvals in other jurisdictions. A similar incident was reported last year when Alphabet’s Waymo taxis suffered the same fate, coming to an abrupt halt due to a power outage.

Despite the above development, the company continues with its innovation plans. Earlier this month, it launched the DuClaw service that allows users to access the OpenClaw agent platform. This will allow users to access all of Baidu’s innovative tools without requiring the technical expertise to set them up. In other words, a technical setback like the one mentioned above is unlikely to detract from the company’s bull thesis.

Baidu Inc. (NASDAQ:BIDU) provides internet search, online entertainment, and online marketing services, including search-based marketing, feed-based marketing, and other services. It is headquartered in Beijing, China.

2. Roper Technologies, Inc. (NASDAQ:ROP)

On April 1, Julian Mitchell of Barclays maintained his Sell rating on the stock, with a price target of $380. The earlier price target from the same analyst was $409. The stock is trading slightly below the current price target, offering only 7.4% upside from here. Other analysts are considerably more bullish on the stock, with a median price target of $464, implying 31.3% upside, according to CNN’s compilation of 22 analyst ratings.

Barclays rating came as the firm adjusted its Q1 earnings expectations for the company. The analyst expressed uncertainty around demand, lowering his estimates as a result. However, positive results from the company’s 2025 acquisitions are expected this year. Last year, the company spent $3.3 billion on vertical software acquisitions. On the Q4 2025 earnings call earlier this year, management said it expects 5%-6% growth contribution from these acquisitions. The company is also spending heavily on stock buybacks, having repurchased $1.8 billion in shares over the past 5 months.

Roper Technologies Inc. (NASDAQ:ROP) makes solutions for enterprises and institutions in healthcare, legal, and insurance sectors. The company offers products that streamline workflow, support diagnostics, and enable precise measurement across various industries. Its famous products include Vertafore, Deltek, Aderant, DAT, and Neptune AMR systems. It was founded in 1890 and is headquartered in Sarasota, Florida.

1. The Progressive Corporation (NYSE:PGR)

On March 24, Jefferies analyst Andrew Andersen maintained a Hold rating on The Progressive Corporation (NYSE:PGR) while cutting the firm’s price target on the shares. The analyst slightly lowered the firm’s price target on the stock from $216 to $215. The adjusted price target implies an additional 5.96% upside from the current levels. The price target adjustment followed the firm’s revision of its financial model to reflect the company’s performance in February.

The Progressive Corporation (NYSE:PGR) signed an underwriting agreement with Goldman Sachs & Co. LLC and TD Securities (USA) LLC on March 23 to raise funds through debt issuance. The company plans to offer $500 million of 4.60% senior notes maturing in 2031 and $1 billion of 5.15% senior notes maturing in 2036. The deal is expected to close on March  26, 2026. It includes standard terms covering protections and obligations for both the underwriters and PGR.

The notes are being issued under an existing 2018 indenture along with a fifth supplement agreement. Interest will be paid twice a year, on March 26 and September 26, starting from September 26, 2026. The maturity dates are set for March 26, 2031, and March 26, 2036. After deducting underwriting fees and other costs, the company expected to receive around  $1.487 billion.

The Progressive Corporation (NYSE:PGR) is an insurance company operating across the United States. The company provides insurance for personal vehicles, including cars, motorcycles, RVs, and watercraft. Additionally, it also offers homeowners’ and renters’ insurance for personal residential properties.

READ NEXT: 8 Best American Stocks to Buy and Hold in 2026 and 12 Best Mid Cap AI Stocks to Buy According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.